Pancreatic Cancer - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 400

Pancreatic Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Pancreatic Cancer - Pipeline Review, H1 2012', provides an overview of the Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. 'Pancreatic Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pancreatic Cancer.
- A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pancreatic Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Pancreatic Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Pancreatic Cancer Therapeutic Products under Development, Key Players in Pancreatic Cancer Therapeutics, Pancreatic Cancer Pipeline Overview, Pancreatic Cancer Pipeline, Pancreatic Cancer Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pancreatic Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Pancreatic Cancer
Pancreatic Cancer Therapeutics under Development by Companies
Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Pancreatic Cancer Therapeutics – Products under Development by Companies
Pancreatic Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Pancreatic Cancer Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Tekmira Pharmaceuticals Corp.
Genentech, Inc.
AbGenomics International, Inc.
Oxford BioMedica plc
Infinity Pharmaceuticals, Inc.
YM BioSciences Inc.
FibroGen, Inc.
Light Sciences Oncology, Inc.
Piramal Healthcare Limited
MediGene AG
BioSante Pharmaceuticals, Inc.
ZIOPHARM Oncology, Inc.
Novartis AG
Samyang Corporation
Aphios Corporation
ImClone Systems Incorporated
Astellas Pharma Inc.
ImmunoGen, Inc.
OSI Pharmaceuticals, Inc.
Pfizer Inc.
SuperGen, Inc.
Taiho Pharmaceutical Co., Ltd.
Yakult Honsha Co., Ltd.
Zeria Pharmaceutical Co Ltd
Exelixis, Inc.
Aduro BioTech
Incyte Corporation
Merck KGaA
Novartis Pharmaceuticals Corporation
Neogenix Oncology Corporation
EntreMed, Inc.
Momenta Pharmaceuticals, Inc.
Anavex Life Sciences Corp.
ValiRx Plc
AEterna Zentaris Inc.
ImmunoCellular Therapeutics, Ltd.
IMMUNOMEDICS, INC
Lorus Therapeutics Inc
Marshall Edwards, Inc.
Molecular Insight Pharmaceuticals, Inc.
Northwest Biotherapeutics, Inc.
Oncolytics Biotech Inc.
Oncothyreon Inc
Peregrine Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
Bionovo, Inc.
Telik, Inc.
VioQuest Pharmaceuticals, Inc.
Karolinska Institutet
CytRx Corporation
Champions Biotechnology, Inc.
Pharmacyclics, Inc.
Array BioPharma Inc.
ProMetic Life Sciences Inc.
Green Cross Corporation
Innocell Corporation
OncoTherapy Science, Inc.
Quest PharmaTech Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Natco Pharma Limited
Sareum Holdings plc
Rexahn Pharmaceuticals, Inc.
MabVax Therapeutics, Inc.
Morphotek, Inc.
Debiopharm Group
D-Pharm Ltd.
Antisense Pharma GmbH
Avanti Therapeutics
Wilex AG
Immupharma Plc
Philogen S.p.A.
Multimmune GmbH
Wellstat Therapeutics Corporation
ERYtech Pharma
Advantagene, Inc.
Alethia Biotherapeutics Inc.
NormOxys, Inc.
Gene Signal International SA.
Heat Biologics, Inc.
MacroGenics, Inc.
Antyra, Inc.
TetraLogic Pharmaceuticals
Azaya Therapeutics, Inc.
Merrimack Pharmaceuticals, Inc.
RESprotect GmbH
ProNAi Therapeutics, Inc.
Jennerex Biotherapeutics, Inc.
Axcentua Pharmaceuticals AB
BioCancell Therapeutics, Inc.
Cornerstone Pharmaceuticals, Inc.
Onconova Therapeutics, Inc
PhytoCeutica, Inc.
Myriad Pharmaceuticals, Inc.
NOXXON Pharma AG
KangLaiTe USA
NovaLead Pharma Pvt. Ltd.
KAEL-GemVax
Mebiopharm Co., Ltd.
Polaris Group
DEKK-TEC, Inc.
IkerChem S.L.
Theradex Systems, Inc.
Regulon Inc.
TAU Therapeutics, LLC
Epeius Biotechnologies Corporation
Immunovative Therapies, Ltd.
Oncozyme Pharma Inc.
CytomX, LLC.
Pancreatic Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PN401 + 5-fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ganitumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glufosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GV1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Estybon + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OTS102 + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SmofKabiven + 5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Human Epidermal Growth Factor Receptor Type I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pancreatic Cancer Therapeutics – Drug Profile Updates
Pancreatic Cancer Therapeutics – Discontinued Products
Pancreatic Cancer Therapeutics - Dormant Products
Pancreatic Cancer – Product Development Milestones
Featured News & Press Releases
May 03, 2012: AREVA Med's Clinical Trial Enrolls Patients At UAB Affiliates
Apr 26, 2012: CytRx Initiates Phase II Clinical Trial With INNO-206 In Pancreatic Cancer
Apr 11, 2012: Threshold Pharma Earns $20m Milestone Payment From Merck For Positive Results From Phase II Trial Of TH-302 In Pancreatic Cancer
Apr 03, 2012: CureFAKtor Pharmaceuticals Demonstrates New Focal Adhesion Kinase Inhibitor Disrupts FAK-VEGFR3 Interaction And Inhibits Pancreatic Tumor Growth
Apr 03, 2012: OncoMed Presents Data On OMP-21M18 At AACR Annual Meeting
Apr 03, 2012: OncoMed Presents Data On OMP-59R5 At AACR Annual Meeting
Apr 03, 2012: TetraLogic Presents Preclinical Data Of Birinapant In Pancreatic Cancer And Lymphoma At AACR Annual Meeting 2012
Apr 02, 2012: Critical Outcome Technologies Receives Second US Patent For COTI-2
Mar 30, 2012: Threshold Presents Positive Phase IIb Trial Results Of TH-302 In Pancreatic Cancer At AACR Annual Meeting
Mar 29, 2012: Oncolytics Biotech To Present Preclinical Research Data On Reovirus At AACR Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Pancreatic Cancer, H1 2012
Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Development by Companies, H1 2012 (Contd..7)
Number of Products under Development by Companies, H1 2012 (Contd..8)
Number of Products under Development by Companies, H1 2012 (Contd..9)
Number of Products under Development by Companies, H1 2012 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Development by Companies, H1 2012 (Contd..9)
Products under Development by Companies, H1 2012 (Contd..10)
Products under Development by Companies, H1 2012 (Contd..11)
Products under Development by Companies, H1 2012 (Contd..12)
Products under Development by Companies, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24)
Bristol-Myers Squibb Company, H1 2012
Johnson & Johnson, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
Viralytics Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Tekmira Pharmaceuticals Corp., H1 2012
Genentech, Inc., H1 2012
AbGenomics International, Inc., H1 2012
Oxford BioMedica plc, H1 2012
Infinity Pharmaceuticals, Inc., H1 2012
YM BioSciences Inc., H1 2012
FibroGen, Inc., H1 2012
Light Sciences Oncology, Inc., H1 2012
Piramal Healthcare Limited, H1 2012
MediGene AG, H1 2012
BioSante Pharmaceuticals, Inc., H1 2012
ZIOPHARM Oncology, Inc., H1 2012
Novartis AG, H1 2012
Samyang Corporation, H1 2012
Aphios Corporation, H1 2012
ImClone Systems Incorporated, H1 2012
Astellas Pharma Inc., H1 2012
ImmunoGen, Inc., H1 2012
OSI Pharmaceuticals, Inc., H1 2012
Pfizer Inc., H1 2012
SuperGen, Inc., H1 2012
Taiho Pharmaceutical Co., Ltd., H1 2012
Yakult Honsha Co., Ltd., H1 2012
Zeria Pharmaceutical Co Ltd, H1 2012
Exelixis, Inc., H1 2012
Aduro BioTech, H1 2012
Incyte Corporation, H1 2012
Merck KGaA, H1 2012
Novartis Pharmaceuticals Corporation, H1 2012
Neogenix Oncology Corporation, H1 2012
EntreMed, Inc., H1 2012
Momenta Pharmaceuticals, Inc., H1 2012
Anavex Life Sciences Corp., H1 2012
ValiRx Plc, H1 2012
AEterna Zentaris Inc., H1 2012
ImmunoCellular Therapeutics, Ltd., H1 2012
IMMUNOMEDICS, INC, H1 2012
Lorus Therapeutics Inc, H1 2012
Marshall Edwards, Inc., H1 2012
Molecular Insight Pharmaceuticals, Inc., H1 2012
Northwest Biotherapeutics, Inc., H1 2012
Oncolytics Biotech Inc., H1 2012
Oncothyreon Inc, H1 2012
Peregrine Pharmaceuticals, Inc., H1 2012
Critical Outcome Technologies Inc., H1 2012
Bionovo, Inc., H1 2012
Telik, Inc., H1 2012
VioQuest Pharmaceuticals, Inc., H1 2012
Karolinska Institutet, H1 2012
CytRx Corporation, H1 2012
Champions Biotechnology, Inc., H1 2012
Pharmacyclics, Inc., H1 2012
Array BioPharma Inc., H1 2012
ProMetic Life Sciences Inc., H1 2012
Green Cross Corporation, H1 2012
Innocell Corporation, H1 2012
OncoTherapy Science, Inc., H1 2012
Quest PharmaTech Inc., H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
Synta Pharmaceuticals Corp., H1 2012
Natco Pharma Limited, H1 2012
Sareum Holdings plc, H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
MabVax Therapeutics, Inc., H1 2012
Morphotek, Inc., H1 2012
Debiopharm Group, H1 2012
D-Pharm Ltd., H1 2012
Antisense Pharma GmbH, H1 2012
Avanti Therapeutics, H1 2012
Wilex AG, H1 2012
Immupharma Plc, H1 2012
Philogen S.p.A., H1 2012
Multimmune GmbH, H1 2012
Wellstat Therapeutics Corporation, H1 2012
ERYtech Pharma, H1 2012
Advantagene, Inc., H1 2012
Alethia Biotherapeutics Inc., H1 2012
NormOxys, Inc., H1 2012
Gene Signal International SA., H1 2012
Heat Biologics, Inc., H1 2012
MacroGenics, Inc., H1 2012
Antyra, Inc., H1 2012
TetraLogic Pharmaceuticals, H1 2012
Azaya Therapeutics, Inc., H1 2012
Merrimack Pharmaceuticals, Inc., H1 2012
RESprotect GmbH, H1 2012
ProNAi Therapeutics, Inc., H1 2012
Jennerex Biotherapeutics, Inc., H1 2012
Axcentua Pharmaceuticals AB, H1 2012
BioCancell Therapeutics, Inc., H1 2012
Cornerstone Pharmaceuticals, Inc., H1 2012
Onconova Therapeutics, Inc, H1 2012
PhytoCeutica, Inc., H1 2012
Myriad Pharmaceuticals, Inc., H1 2012
NOXXON Pharma AG, H1 2012
KangLaiTe USA, H1 2012
NovaLead Pharma Pvt. Ltd., H1 2012
Esperance Pharmaceuticals, Inc., H1 2012
Omeros Corporation, H1 2012
Transtech Pharma, Inc., H1 2012
BiPar Sciences, Inc., H1 2012
Welichem Biotech Inc., H1 2012
Oncolys BioPharma Inc., H1 2012
Globeimmune, Inc., H1 2012
NewLink Genetics Corporation, H1 2012
Tragara Pharmaceuticals, Inc., H1 2012
PharmaMar, S.A., H1 2012
Quintessence Biosciences, Inc., H1 2012
AB Science, H1 2012
Tigris Pharmaceuticals, Inc., H1 2012
Cylene Pharmaceuticals, Inc., H1 2012
Lipopharma, H1 2012
Nereus Pharmaceuticals, Inc., H1 2012
Medisyn Technologies, Inc., H1 2012
Perseus Proteomics, Inc., H1 2012
Pique Therapeutics, H1 2012
Cellceutix Pharmaceuticals, Inc., H1 2012
Eleison Pharmaceuticals, Inc., H1 2012
Targa Therapeutics Corp., H1 2012
KAEL-GemVax, H1 2012
Mebiopharm Co., Ltd., H1 2012
Polaris Group, H1 2012
DEKK-TEC, Inc., H1 2012
IkerChem S.L., H1 2012
Theradex Systems, Inc., H1 2012
Regulon Inc., H1 2012
TAU Therapeutics, LLC, H1 2012
Epeius Biotechnologies Corporation, H1 2012
Immunovative Therapies, Ltd., H1 2012
Oncozyme Pharma Inc., H1 2012
CytomX, LLC., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Pancreatic Cancer Therapeutics – Drug Profile Updates
Pancreatic Cancer Therapeutics – Discontinued Products
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..1)
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..2)
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..3)
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..4)
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..5)
Pancreatic Cancer Therapeutics – Dormant Products
Pancreatic Cancer Therapeutics – Dormant Products (Contd..1)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..2)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..3)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..4)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..5)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..6)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..7)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..8)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..9)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..10)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..11)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..12)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..13)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..14)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..15)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..16)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..17)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..18)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..19)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..20)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..21)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..22)
Pancreatic Cancer Therapeutics – Dormant Products (Contd..23)

List of Figures
Number of Products under Development for Pancreatic Cancer, H1 2012
Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Prostate Cancer - Pipeline Review, H1 2013
• Obesity - Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Osteoporosis - Pipeline Review, H1 2013
• Eczema - Pipeline Review, H1 2013
• Inflammatory Bowel Disease - Pipeline Review, H1 2013
• Diabetes - Pipeline Review, H1 2012
• Cystic Fibrosis - Pipeline Review, H1 2013
• Acne And Related Disorders - Pipeline Review, H1 2013